Company Analysis
Sign in

Immutep Limited (IMMP)

Nasdaq: IMMP · Pharmaceutical Preparations · Sydney,, AU · filing with the SEC since 2012
Full chart Alerts Compare
Grade5.7
◀ Past 5.7● Present 5.5▶ Future 5.9
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueA$10.3M+31.8%
Net income-A$61.4M-43.8%
Earnings per shareA$-0.04-18.5%
Operating cash flow-A$62.0M-78.2%
CashA$67.4M-58.3%
Debtn/a
Shareholders’ equityA$144M-24.2%
Shares, diluted1.46B+21.2%
Return on equity-42.8%
The recordfrom its filings
Filings in 202630
Newest filingNov 10 · 6-K
Annual reportOct 23, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in AUD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton IMMP · research, not advice